Arthritis und Rheuma 2017; 37(03): 191-195
DOI: 10.1055/s-0037-1618425
Kinderrheumatologie/Übersichtsarbeit
Schattauer GmbH

Aktuelles zu Enthesitis-assoziierter Arthritis und juvenilen Spondyloarthritiden

Current issues in enthesitis-related arthritis und juvenile spondylo arthritides
B. Hügle
1   Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen
› Author Affiliations
Further Information

Publication History

Publication Date:
27 December 2017 (online)

Zusammenfassung

Spondyloarthritiden im Kindesalter zu erkennen, insbesondere früh im Krankheitsverlauf, ist eine besondere Herausforderung für den klinischen Rheumatologen. Die Symptome und Anzeichen bei Erkrankungsbeginn sind im Vergleich zu denen bei Erwachsenen deutlich unterschiedlich, mit häufigerer Arthritis von peripheren Gelenken, Enthesitis und Tarsitis. Juvenile Spondyloarthritiden können neben der archetypischen Enthesitis-assoziierten Arthritis auch in anderen Formen, einschließlich Psoriasis-Arthritis und undifferenzierte Arthritis, auftreten, was eine Abgrenzung schwierig macht. Die Langzeitprognose für Patienten mit juveniler SpA ist variabel und abhängig von den herangezogenen Studien. Diese Inkonsistenz ist wahrscheinlich eine Folge verschiedener Faktoren einschließ-lich der Verwendung unterschiedlicher Klassifikationssysteme, aber auch der untersuchten Bevölkerung. Die Studienlage zu Behandlung und Verlauf der Spondyloarthritiden im Kindesalter ist noch immer sehr dürftig, in den vergangenen Jahren ist vor allem die Datenlage zur Wirksamkeit von TNF-Antagonisten untermauert worden. Langzeitremissionen bei juvenilen Spondyloarthritiden ohne Medikamente sind jedoch weiterhin selten.

Summary

To recognize spondyloarthritides in childhood, especially early in the disease course, is challenging for the clinical rheumatologist. Signs and symptoms at the start of the disease course are markedly different compared to adults, with more frequent arthritis in peripheral joints, enthesitis and tarsitis. Besides the archetypical enthesitis-related arthritis, juvenile spondyloarthritides can also occur in other forms, such as psoriatic arthritis and undifferentiated arthritis, which makes discrimination difficult. Long term prognosis for patients with juvenile spondyloarthritis is variable and depends on the studies consulted. This inconsistency probably is the result of different factors including usage of various classification systems as well as the population investigated. The evidence base for treatment and course of spondyloarthri-tides in childhood is rather thin; research in recent years has mostly demonstrated efficacy of TNF antagonists. However, long term remissions in juvenile spondyloarthritides off medication are still a rare occurence.

 
  • Literatur

  • 1 Tse SM, Laxer RM. New advances in juvenile spondyloarthritis. Nat Rev Rheumatol 2012; 8 (05) 269-279.
  • 2 Bertilsson L, Andersson-Gare B, Fasth A. et al. Disease course, outcome, and predictors of outcome in a population-based juvenile chronic arthritis cohort followed for 17 years. J Rheumatol 2013; 40 (05) 715-724.
  • 3 Selvaag AM, Aulie HA, Lilleby V, Flato B. Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis. Ann Rheum Dis 2016; 75 (01) 190-195.
  • 4 Minden K, Niewerth M. Klinische Formen der juvenilen idiopathischen Arthritis und ihre Klassifikation. Z Rheumatol 2008; 67 (02) 100 (2_6) 8-10.
  • 5 Petty RE, Southwood TR, Manners P. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31 (02) 390-392.
  • 6 Rosenberg AM, Petty RE. A syndrome of seronegative enthesopathy and arthropathy in children. Arthritis Rheum 1982; 25 (09) 1041-1047.
  • 7 Dougados M, van der Linden S, Juhlin R. et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34 (10) 1218-1227.
  • 8 Rudwaleit M, van der Heijde D, Landewe R. et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011; 70 (01) 25-31.
  • 9 van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27 (04) 361-368.
  • 10 Flato B, Hoffmann-Vold AM, Reiff A. et al. Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study. Arthritis Rheum 2006; 54 (11) 3573-3582.
  • 11 Minden K, Niewerth M, Listing J. et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002; 46 (09) 2392-2401.
  • 12 Burgos-Vargas R, Vazquez-Mellado J, Cassis N. et al. Genuine ankylosing spondylitis in children: a case-control study of patients with early definite disease according to adult onset criteria. J Rheumatol 1996; 23 (12) 2140-2147.
  • 13 O‘Shea FD, Boyle E, Riarh R. et al. Comparison of clinical and radiographic severity of juvenile-onset versus adult-onset ankylosing spondylitis. Ann Rheum Dis 2009; 68 (09) 1407-1412.
  • 14 Baek HJ, Shin KC, Lee YJ. et al. Juvenile onset ankylosing spondylitis (JAS) has less severe spinal disease course than adult onset ankylosing spondylitis (AAS): clinical comparison between JAS and AAS in Korea. J Rheumatol 2002; 29 (08) 1780-1785.
  • 15 Weiss PF, Beukelman T, Schanberg LE. et al. Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry. J Rheumatol 2012; 39 (12) 2341-2351.
  • 16 Burgos-Vargas R, Clark P. Axial involvement in the seronegative enthesopathy and arthropathy syndrome and its progression to ankylosing spondylitis. J Rheumatol 1989; 16 (02) 192-197.
  • 17 Cabral DA, Oen KG, Petty RE. SEA syndrome revisited: a longterm followup of children with a syndrome of seronegative enthesopathy and arthropathy. J Rheumatol 1992; 19 (08) 1282-1285.
  • 18 Moll JM, Wright V. Normal range of spinal mobility. An objective clinical study. Ann Rheum Dis 1971; 30 (04) 381-386.
  • 19 Stoll ML, Zurakowski D, Nigrovic LE. et al. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum 2006; 54 (11) 3564-3572.
  • 20 Butbul Aviel Y, Tyrrell P, Schneider R. et al. Juvenile Psoriatic Arthritis (JPsA): juvenile arthritis with psoriasis?. Pediatr Rheumatol Online J 2013; 11 (01) 11
  • 21 Stoll ML, Nigrovic PA. Subpopulations within juvenile psoriatic arthritis: a review of the literature. Clin Dev Immunol 2006; 13 (2-4) 377-380.
  • 22 Mielants H, Veys EM, Cuvelier C. et al. Gut inflammation in children with late onset pauciarticular juvenile chronic arthritis and evolution to adult spondyloarthropathy - a prospective study. J Rheumatol 1993; 20 (09) 1567-1572.
  • 23 Pichler J, Ong C, Shah N. et al. Histopathological features of gastrointestinal mucosal biopsies in children with juvenile idiopathic arthritis. Pediatr Res 2016; 79 (06) 895-901.
  • 24 Stamato T, Laxer RM, de Freitas C. et al. Prevalence of cardiac manifestations of juvenile ankylosing spondylitis. Am J Cardiol 1995; 75 (10) 744-746.
  • 25 Brooks CD. Sulfasalazine for the management of juvenile rheumatoid arthritis. J Rheumatol 2001; 28 (04) 845-853.
  • 26 van Rossum MA, Fiselier TJ, Franssen MJ. et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998; 41 (05) 808-816.
  • 27 Beukelman T, Patkar NM, Saag KG. et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis care & research 2011; 63 (04) 465-482.
  • 28 Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 2005; 52 (07) 2103-2108.
  • 29 Hugle B, Burgos-Vargas R, Inman RD. et al. Long-term outcome of anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis. Clin Exp Rheumatol 2014; 32 (03) 424-431.
  • 30 Sulpice M, Deslandre CJ, Quartier P. Efficacy and safety of TNF alpha antagonist therapy in patients with juvenile spondyloarthropathies. Joint Bone Spine 2009; 76 (01) 24-27.
  • 31 Horneff G, Burgos-Vargas R, Constantin T. et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis 2014; 73 (06) 1114-1122.
  • 32 Horneff G, Foeldvari I, Minden K. et al. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study. Arthritis Rheumatol 2015; 67 (08) 2240-2249.
  • 33 Burgos-Vargas R, Tse SM, Horneff G. et al. A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis. Arthritis care & research 2015; 67 (11) 1503-1512.
  • 34 Dueckers G, Guellac N, Arbogast M. et al. Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 2012; 142 (02) 176-193.
  • 35 Stone M, Warren RW, Bruckel J. et al. Juvenile-onset ankylosing spondylitis is associated with worse functional outcomes than adult-onset ankylosing spondylitis. Arthritis Rheum 2005; 53 (03) 445-451.
  • 36 Jadon DR, Shaddick G, Jobling A. et al. Clinical outcomes and progression to orthopedic surgery in juvenile- versus adult-onset ankylosing spondylitis. Arthritis care & research 2015; 67 (05) 651-657.
  • 37 Taxter AJ, Wileyto EP, Behrens EM, Weiss PF. Patient-reported Outcomes across Categories of Juvenile Idiopathic Arthritis. J Rheumatol 2015; 42 (10) 1914-1921.
  • 38 Otten MH, Prince FH, Twilt M. et al. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis - data from the dutch arthritis and biologicals in children register, 1999-2010. J Rheumatol 2011; 38 (10) 2258-2263.
  • 39 Cassidy JT, Petty RE. Textbook of pediatric rheumatology, 5th ed. Philadelphia, PA: Elsevier Saunders; 2005. xvi 792
  • 40 A Resident‘s Guide To Pediatric Rheumatology - Deutsche Übersetzung Toronto: The Hospital for Sick Children; 2016